Introduction
Amplification or overexpression of the human epidermal growth factor receptor 2 (HER2) oncogene and oncoprotein, respectively, occurs in about 15-20% of primary breast cancers.
Patients with HER2-positive breast cancer benefit from treatment with anti-HER2 therapies including the monoclonal antibody trastuzumab (1, 2) . In the adjuvant setting, pivotal randomized clinical trials including the HERceptin Adjuvant (HERA) trial (1) showed that 1 year is the optimal duration for trastuzumab therapy in these patients (3) . Despite the improvements of outcome achieved by anti-HER2 therapies, clinical resistance to trastuzumab remains a significant problem; long-term follow up indicates that a significant proportion of patients with early HER2-positive breast cancer will experience recurrence of their disease (4) . The overall objective of TransHERA, the translational research sub-study of HERA, was to identify markers that can predict sensitivity or resistance to adjuvant trastuzumab therapy.
Some clinical parameters, including histologic type and tumor stage are associated with the magnitude of benefit from adjuvant trastuzumab because of their relationship with prognosis but they do not relate to proportional benefit from trastuzumab (5) . We have reported that HER2-positive early breast cancers that are estrogen receptor (ER)-positive by immunohistochemistry with low HER2:CEP17 FISH ratio, or with higher mRNA expression of ESR1 levels derived significantly less benefit from adjuvant trastuzumab after chemotherapy in TransHERA (6) .
Several mechanisms of resistance to HER2 blockade have been described to date including activation of the phosphatidylinositol-3-kinase (PI3K) pathway (7, 8) . Cell cycle regulators have also been suggested to predict resistance or response to trastuzumab treatment (9, 10) . Cyclins, their associated cyclin-dependent kinases (CDKs), and CDK inhibitory proteins play a central role in cell cycle progression and may also affect response to trastuzumab (10) . In addition, topoisomerase 2-alpha (TOP2A) alterations may also have the potential to act as a predictive biomarker of trastuzumab benefit (11, 12) .
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In this study, we evaluated the prognostic/predictive value of p27, cyclin D1, TOP2A, and Ki67 protein expression in patients with HER2-positive primary breast cancer who were enrolled in the HERA and participated in TransHERA.
Patients and Methods

Study design and participants
The TransHERA sub-study included patients who participated in the HERA study (Breast
open-label, phase III randomized study enrolling 5102 women with HER2-positive (overexpressed or amplified) primary breast cancer (1) , and who consented to evaluation of their tumor tissue for research purposes. All patients had at least 4 courses of adjuvant standard chemotherapy, and were randomized to one year or two years of adjuvant trastuzumab administered intravenously every 3 weeks, or to observation (no trastuzumab arm). The observation patients were allowed to selectively crossover to trastuzumab (either 1 or 2 year), if they were alive and disease free as of May 16 th 2005, based on the significant benefit in disease-free survival (DFS) for patients treated with 1-year trastuzumab versus observation shown at the first interim analysis. The study was conducted according to HERA master and Trans-HERA sub-study protocols; with adherence to country specific ethics, regulatory requirements and REMARK recommendations (13) .
Specimen collection and immunostaining for biomarkers
Formalin-fixed, paraffin-embedded (FFPE) tumor tissue blocks were obtained at the time of surgery before adjuvant therapy. Paraffin blocks were stored at room temperature and were identifiable only by an identification number assigned to each patient at randomization. 
Statistical analyses
The primary analysis was an intention-to-treat analysis. To take into account selective crossover, additional analyses were performed. These included a censored, an IPCW (Inverse Probability Censored Weighting), and an early events analysis. In the censored analysis, no further follow-up is taken into account for observation patients that crossed over to a trastuzumab arm, at the time of crossing over. In the IPCW analysis, the additional follow-up for these patients is substituted by weighting appropriately the patients who did not cross over. In the early events analysis, only 9 events occurring up to 2.2 years of median follow-up were taken into account. These events, important in the context of translational research, occurred at a time when crossover was minimal.
The primary endpoint of the study was DFS, defined as time from randomization to first occurrence of local, regional, distant recurrence, contralateral breast cancer including ductal carcinoma in situ (DCIS), second non-breast malignant disease or death from any cause. Overall survival (OS) was a secondary endpoint, defined as the time from randomization to death from any cause. In the present analysis the 1-year and 2-year trastuzumab arms were combined into a single arm (3). Fisher's exact and Mantel-Haenszel or Kruskal-Wallis tests were used in order to explore potential differences between groups. The distributions of the markers were shown graphically via histograms, whereas their associations were explored by scatter plots, box-plots, and the Spearman correlation coefficient. In all exploratory analyses, results with a two-sided p-value less than 0.05 were considered significant.
Cox proportional hazards regression for DFS and OS, was the main analysis tool in order to assess prognostic or predictive effect of the markers. Marker and treatment effects were added into the models, along with their interaction terms. Hazard ratios (HRs), along with corresponding 95% confidence intervals (CIs), were used to show the relationship between markers and outcome. The (categorization based on tertiles) (6) main and predictive effects] was performed, and the best model was chosen by the backward selection method with removal criterion a p-value>0.10.
Departures from the proportional hazards assumption were assessed based on the Schoenfeld residuals (14). The False Discovery Rate (FDR) method was implemented to account for multiple testing (15) .
Biomarkers were analyzed either as continuous or as categorical variables, based on the following prospectively specified categorization scheme: TOP2A percent: ≤5 versus >5, Ki67 according to tertiles, cyclin D1 percent: ≤10 versus >10, p27 percent: ≤70 versus >70 (12, (16) (17) (18) . Whenever a continuous variable showed a significant interaction with treatment not translated when the marker was categorized in two groups, further exploration using tertiles for the corresponding marker was performed.
Results
Study Population
Out of the 5099 HERA patients (excluding three patients due to missing informed consent documentation), there were 1162 participating in TransHERA. From these, 862 patients (17% of the whole study population) had available information on the protein expression on at least one of the following biomarkers: TOP2A, Ki67, cyclin D1, or p27.
Patient and tumor baseline characteristics, as well as information on DFS and OS for the current analysis cohort and the remainder of the HERA population are shown in Tables S1-4 . Tumor size, ER measured locally, race, region, and prior neoadjuvant chemotherapy were baseline characteristics differing substantially between the TransHERA group and the remainder of HERA cohort. For both DFS and OS, the observed magnitude of the trastuzumab benefit in the TransHERA group is similar to that detected in the HERA cohort. In the current analysis cohort, the treatment effect is significant for DFS, whereas for OS the indicated beneficial effect does not reach significance, probably due to the small event number (DFS: In the current analysis cohort, 301 patients were randomized to the observation arm and 561 to the combined trastuzumab arm (1-or 2-year trastuzumab). All characteristics of the patients were balanced between the two treatment groups ( Table 1) . Out of the 248 observation patients eligible to cross over, 188 (74.3%) switched to trastuzumab treatment.
Biomarker distributions and associations
Frequency distribution on biomarker categories overall and according to treatment arms are shown in (Tables S7-8) .
When biomarkers were treated as continuous variables, the only marker found to have a significant predictive effect on DFS was cyclin D1 (interaction p=0.006; Table S10 ). This effect remained statistically significant after adjusting for clinical parameters (p=0.0046, FDR p=0.045; Table   S10 ). Higher levels of cyclin D1 were significantly associated with better DFS in the observation (Tables S11-12 ).
To further investigate the predictive ability of cyclin D1, a categorization based on tertiles was also considered (low, intermediate and high; p=0.013, FDR p=0.078; Figure 1C) The above findings on cyclin D1 did not change after adjusting for the remaining three markers.
In particular, the interaction term between treatment and cyclin D1 (high versus low) was found significant (p=0.010; FDR p=0.068).
No significant interaction was detected between treatment and any of the four biomarkers (both as continuous and categorical variable), with respect to OS. The results of the early events, censored and IPCW analyses did not lead to different conclusions from the ITT analysis.
Discussion
Results of the HERA trial demonstrated that one year of adjuvant trastuzumab treatment of earlystage HER2-positive breast cancer patients provides a significant DFS and OS benefit compared with observation and the degree of benefit was similar to that with 2 years' trastuzumab. This has resulted in one year of trastuzumab being the standard of care for patients with HER2-positive early breast cancer (1, 3) . It also allowed us to analyze the outcome data from the 1 year and 2 year 14 trastuzumab arms of HERA as a single treatment arm. Our study is a step forward in establishing the impact of molecular biomarkers on the outcome of a large group of patients in this study cohort.
Of great importance we report for the first time within the context of an adjuvant randomized trastuzumab trial that the positive and negative cell cycle regulators p27 and cyclin D1 respectively have predictive value in HER2-positive early breast cancer: only patients with low p27 expression or lower levels of cyclin D1 expression benefited from trastuzumab treatment in the TransHERA cohort.
Strengths of this study were the randomized design of the clinical trial from which the patients were derived, the relatively large size of the TransHERA population, the biomarker analysis using validated assays in a central laboratory and the data analyses being conducted on a formal statistical analysis plan that included adjustment on standard prognostic variables. A weakness is that the
TransHERA group was only a modest proportion of the HERA trial and although the outcome data were similar in those patients included or not included in TransHERA it cannot be concluded that our findings apply fully across the whole trial population. In addition, although the markers were selected as potential candidate markers on the basis of previous findings, the predictive role of p27 and cyclin D1 still requires validation before being accepted as clinically valid and worthy of investigation for clinical utility.
We applied a previously defined cut-off for p27 positivity (high 70% p27-positive tumor cells).
This had previously been used to assess the clinical relevance of p27 in postmenopausal hormone receptor-positive breast cancer patients who received tamoxifen for 5 years in Austrian Breast and Colorectal Cancer Study Group Trial 06 (17) . In that retrospective analysis, women with high p27 expression had a significantly longer DFS and OS as compared to women with low p27 expression; this finding is similar to what we report in this HER2-positive breast cancer cohort, where p27
showed strong favorable prognostic significance in the observation group.
It has previously been described that induction of p27, a CDK inhibitor functioning as distal downstream regulator of several oncogenic signaling pathways, is one of the key modes of action 15 of HER2-targeting antibodies in breast cancer (19) (20) (21) (22) , with an increase in p27 thought to cause proliferating cells to exit the cell cycle and thereby undergo apoptosis (23) . It may be that breast cancer patients with HER2-positive, p27 low expressing tumors benefit more from trastuzumab because the effect of p27 up-regulation may be greater in these patients compared to patients whose tumors have p27 high expression. Interestingly, down-regulation of p27 has been associated with trastuzumab resistance in breast cancer cells (9) and trastuzumab-resistant cells have been reported
to have decreased levels of p27 and exogenous addition of trastuzumab to increase trastuzumab sensitivity (9) . Thus it seems likely that decreased p27 levels in the tumors of trastuzumab-resistant patients are mediated by different mechanisms compared to low p27 expression in trastuzumabnaive patients. One potential mechanism in trastuzumab-resistant cells could be overexpression of insulin-like growth factor I receptor (IGF-IR) (24) . It has been shown that the mechanism by which IGF-IR confers resistance to trastuzumab involves increased degradation of p27 by the ubiquitin/proteasome degradation machinery (24) . Thus sensitivity and resistance to trastuzumab in HER2-overexpressing cells is critically dependent on p27 levels.
Only limited information on the clinical role of p27 as a predictive marker for trastuzumab therapy in breast cancer is available in the literature. In a Japanese trial, the association of p27 and other biomarkers with pathological complete response (pCR) and survival was studied in women with HER2-positive breast cancer who received neo-adjuvant trastuzumab-based chemotherapy (25) . In this study, the pCR rate was significantly higher in patients whose tumors had low expression of p27 (defined as <75% p27-positive tumor cells) compared to patients with high p27 expression (71% versus 50%, respectively, p=0.025) (25) . This is in line with our observation that patients with low p27 expression in their tumors benefit more from trastuzumab treatment than patients with high p27 expression in their tumors. High grading, low ER, low PgR and high Ki67 also predicted pCR in the Japanese patient cohort. However, we could not confirm the predictive value of these biomarkers in TransHERA patients.
16
If the result that only HER2-positive early breast cancer patients with low p27 expression in their tumors benefit from trastuzumab treatment is validated, this finding may help to optimize the adjuvant treatment of patients with HER2-positive breast cancer in the future.
In summary, we have analyzed p27 protein expression in early stage HER2-positive breast cancers from women who had been enrolled into the HERA trial. We have demonstrated that, by using a predefined cut-off, low p27 expression may be associated with benefit from adjuvant trastuzumab treatment. CI denotes confidence interval. 
